Skip to main content

Vials of H5N1 flu vaccine by Beijing-based drug maker Sinovac Biotech Ltd. are seen during production at Sinovac facilities in Beijing.

ANDY WONG/ASSOCIATED PRESS

Canada's National Microbiology Laboratory has isolated live H5N1 virus from respiratory specimens taken from an Alberta woman who died recently from infection with that bird flu virus.

The Winnipeg-based lab is working in collaboration with Alberta's provincial laboratory to sequence the entire genome of the virus, which the woman is believed to have contracted during a three-week trip to China in December.

The woman was unwell on her return trip on Dec. 27, was hospitalized Jan. 1 and died Jan. 3.

Story continues below advertisement

This is the first time an H5N1 infection has been detected in North America.

Isolating the virus allows the national lab to do research on this H5N1.

In an e-mailed response to questions, officials at the Winnipeg lab say copies of the virus will be shared with the U.S. Centers for Disease Control, which is part of the World Health Organization's network of influenza reference laboratories.

They also say the full genetic blueprint of the virus will be entered into GISAID, an online influenza database accessible to flu researchers from around the globe.

Canadian and Alberta health officials have been working with authorities from China and from the WHO to try to figure out how the Alberta woman became infected with H5N1.

The woman was a nurse from Red Deer who was originally from China. She travelled there with her mother. The pair spent their entire vacation in Beijing and reportedly did not visit poultry markets or have exposure to poultry while there.

While H5N1 is considered to be endemic in China, there have been few recent reports of it there and none from Beijing. That fact, along with the woman's apparent lack of exposure to poultry, leaves authorities puzzled as to how she was exposed.

Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter